Recent announcements
POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022
The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at https://hub.pointbiopharma.com/controlarm
POINT Biopharma to Participate in Upcoming Investor Conferences
POINT will participate in the following summer investor conferences:
POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial
Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications (a Novartis Company).
POINT Biopharma to Participate in Upcoming Investor Conferences
Today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will participate in the following upcoming investor conferences.
POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy.
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update
POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program; trial is expected to commence this summer.
POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial
Clinical doses continue to be manufactured and shipped from the Company’s Indianapolis, Indiana facility
First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe. Sites initiated in France, Sweden, Netherlands, and the UK, with randomization in each expected this summer.